#USA #San Diego #Immunotherapy #Cancer Vaccine #NEUVOGEN

NEUVOGEN Expands Its Expertise with New Board Members

In a significant leap forward for cancer treatment, NEUVOGEN, Inc., based in San Diego, announced the appointments of two illustrious figures in the field of immunology and cancer vaccines to its Scientific Advisory Board (SAB) on April 16, 2025. Dr. James P. Allison and Dr. Padmanee Sharma, both esteemed researchers, bring with them a wealth of knowledge and experience that aligns perfectly with NEUVOGEN's mission of advancing cancer immunotherapy.

A Celebration of Expertise

Todd Binder, CEO of NEUVOGEN, expressed enthusiasm over these pivotal additions, indicating that these appointments not only bolster the board’s existing expertise but also enhance the company’s trajectory in the immunological frontier of cancer therapies. Dr. Allison is renowned for his groundbreaking work that led to the 2018 Nobel Prize in Physiology or Medicine. Alongside his research partner, Dr. Tasuku Honjo, he discovered the mechanisms of cancer therapy by inhibiting negative immune regulation, reshaping modern cancer treatments.

Dr. Allison currently serves as the Regental Professor and Chair of Immunology, alongside being the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. His invaluable insights into T cell regulation and the architecture of immune responses are anticipated to guide NEUVOGEN through an ambitious phase of development as it focuses on its proprietary NGEN-143 platform.

Pioneering Research on Immune Checkpoint Therapy

Joining Dr. Allison, Dr. Padmanee Sharma is an equally distinguished figure in oncology and immunology. As the Director of Scientific Programs for the same institute, she has been at the forefront of immune checkpoint therapy, pushing the boundaries of how the body’s immune system can be leveraged to combat cancer. Her accolades include receiving the Emil Frei III Award and the Coley Award for her contributions to tumor immunology, and she was recognized with the Women in Science with Excellence (WISE) award in 2020. Sharma’s role will be integral in aligning the research and clinical applications that NEUVOGEN aims to develop.

Advancing Cancer Immunotherapy with NEUVOGEN’s NGEN-143

NEUVOGEN is committed to pioneering next-generation cancer vaccines that present a broad array of tumor-associated and tumor-specific antigens. The company’s flagship product, NGEN-143, is engineered specifically for non-small cell lung cancer patients. By utilizing six allogeneic tumor cell lines modified with proprietary activation technology, NGEN-143 seeks to provide a comprehensive attack on cancer by activating the body’s immune response. This approach not only aims to treat existing tumors but also has the potential to prevent cancer recurrence through enhanced immune vigilance.

A Vision for the Future

NEUVOGEN’s goal is clear: to develop therapeutic cancer vaccines that meaningfully enhance patients’ lives while minimizing side effects. The expertise of Dr. Allison and Dr. Sharma may be instrumental in achieving these objectives as NEUVOGEN continues to refine its offerings and expand its clinical trial endeavors.

As NEUVOGEN accelerates its mission with these significant board appointments, the biotechnology firm has positioned itself as a noteworthy contender in the oncology space, dedicated to transforming the landscape of cancer treatment now and in the years ahead.

For more information on NEUVOGEN and its initiatives, please visit www.neuvogen.com.